Answers are grounded in this paper and cite their sources.
Background/Objectives: Ischemic brain injury involves parallel oxidative, inflammatory, and vascular cascades. Olmesartan medoxomil and apigenin act on complementary arms and can serve this purpose. This study developed a self-nanoemulsifying drug delivery system (SNEDDS) co-loaded with both agents for intranasal use. Constrained mixture design was used to determine its actual composition. Methods: Oil and cosolvent were selected by saturation solubility and surfactant by emulsification transmittance. The proportions of Kolliphor EL (40–70% w/w), poly(ethylene glycol) 400 (5–30% w/w), and Imwitor 308 (20–40% w/w) were treated as mixture variables and each drug’s solubility as the response. Desirability analysis identified the optimum composition, which was experimentally verified. After that, it was compared with a drug suspension for permeation across excised goat nasal mucosa in Franz diffusion cells. Results: Apigenin solubility followed a linear mixture model and olmesartan medoxomil a quadratic model. The optimum composition (52.33% Kolliphor EL, 27.67% poly(ethylene glycol) 400, 20.00% Imwitor 308) gave observed solubilities of 11.82 and 6.91 mg/g, within the 95% prediction intervals. Steady-state flux rose from 0.85 ± 0.68 to 8.46 ± 2.51 µg/cm2/h for olmesartan medoxomil and from 0.18 ± 0.17 to 10.06 ± 3.63 µg/cm2/h for apigenin. Conclusions: A constrained mixture design identified a SNEDDS composition that accommodated both drugs and markedly increased their transport across excised nasal mucosa relative to a suspension. These findings establish a formulation basis for the intranasal administration of this drug combination.
No takes yet. Share an insight, caveat, or question.
Elzayat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: